

1 **Genetic Factors Associated with Prostate Cancer**
2 **Conversion from Active Surveillance to Treatment**

3
4 Yu Jiang,^{1,41} Travis J. Meyers,^{1,41} Adaeze A. Emeka,² Lauren Folgosa Cooley,² Phillip R.
5 Cooper,² Nicola Lancki,³ Irene Helenowski,³ Linda Kachuri,¹ Daniel W. Lin,^{4,5} Janet L.
6 Stanford,^{6,7} Lisa F. Newcomb,^{4,5} Suzanne Kolb,^{6,7} Antonio Finelli,⁸ Neil E. Fleshner,⁸ Maria
7 Komisarenko,⁸ James A. Eastham,⁹ Behfar Ehdaie,⁹ Nicole Benfante,⁹ Christopher J.
8 Logothetis,¹⁰ Justin R. Gregg,¹⁰ Cherie A. Perez,¹⁰ Sergio Garza,¹⁰ Jeri Kim,¹⁰ Leonard S.
9 Marks,¹¹ Merdie Delfin,¹¹ Danielle Barsa,¹¹ Danny Vesprini,¹² Laurence H. Klotz,¹² Andrew
10 Loblaw,¹² Alexandre Mamedov,¹² S. Larry Goldenberg,¹³ Celestia S. Higano,¹³ Maria Spillane,¹³
11 Eugenia Wu,¹³ H. Ballentine Carter,¹⁴ Christian P. Pavlovich,¹⁴ Mufaddal Mamawala,¹⁴ Tricia
12 Landis,¹⁴ Peter R. Carroll,¹⁵ June M. Chan,^{1,15} Matthew R. Cooperberg,^{15,16} Janet E. Cowan,¹⁵
13 Todd M. Morgan,¹⁷ Javed Siddiqui,¹⁸ Rabia Martin,¹⁸ Eric A. Klein,¹⁹ Karen Brittain,¹⁹ Paige
14 Gotwald,¹⁹ Daniel A. Barocas,²⁰ Jeremiah R. Dallmer,^{20,21} Jennifer B. Gordetsky,^{20,22} Pam
15 Steele,²⁰ Shilajit D. Kundu,² Jazmine Stockdale,² Monique J. Roobol,²³ Lionne D.F.
16 Venderbos,²³ Martin G. Sanda,²⁴ Rebecca Arnold,²⁴ Dattatraya Patil,²⁴ Christopher P. Evans,²⁵
17 Marc A. Dall'Era,²⁵ Anjali Vij,²⁵ Anthony J. Costello,²⁶ Ken Chow,²⁶ Niall M. Corcoran,²⁶ Soroush
18 Rais-Bahrami,^{27,28} Courtney Phares,²⁷ Douglas S. Scherr,²⁹ Thomas Flynn,²⁹ R. Jeffrey
19 Karnes,³⁰ Michael Koch,³¹ Courtney Rose Dhondt,³¹ Joel B. Nelson,³² Dawn McBride,³² Michael
20 S. Cookson,³³ Kelly L. Stratton,³³ Stephen Farriester,³³ Erin Hemken,³³ Walter M. Stadler,³⁴
21 Tuula Pera,³⁴ Deimante Banionyte,³⁴ Fernando J. Bianco Jr.,³⁵ Isabel H. Lopez,³⁵ Stacy Loeb,³⁶
22 Samir S. Taneja,³⁶ Nataliya Byrne,³⁶ Christopher L. Amling,³⁷ Ann Martinez,³⁷ Luc Boileau,³⁷
23 Franklin D. Gaylis,³⁸ Jacqueline Petkewicz,³⁹ Nicholas Kirwen,³⁹ Brian T. Helfand,³⁹ Jianfeng
24 Xu,³⁹ Denise M. Scholtens,³ William J. Catalona,^{2,42} John S. Witte^{1,15,16,40,42}

25

26 **Author Affiliations:**

27 ¹Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
28 94158, USA

29 ²Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

30 ³Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of
31 Medicine, Chicago, IL 60611, USA

32 ⁴Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle,
33 WA 98109, USA

34 ⁵Department of Urology, University of Washington, Seattle 98195, WA, USA

35 ⁶Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences,
36 Seattle, WA 98109, USA

37 ⁷Department of Epidemiology, University of Washington, School of Public Health, Seattle, WA 98195, USA

38 ⁸Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network,
39 Toronto, Ontario, Canada

40 ⁹Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

41 ¹⁰Departments of Genitourinary Medical Oncology and Urology, University of Texas M.D. Anderson Cancer
42 Center, Houston, TX, USA

43 ¹¹Department of Urology, David Geffen School of Medicine at UCLA, USA

44 ¹²Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, ON,
45 Canada

46 ¹³Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

47 ¹⁴Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

48 ¹⁵Department of Urology, University of California, San Francisco, San Francisco, CA, USA

49 ¹⁶Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San
50 Francisco, CA, USA

51 ¹⁷Department of Urology, University of Michigan, Ann Arbor, MI, USA

52 ¹⁸Department of Pathology, University of Michigan, Ann Arbor, MI, USA

53 ¹⁹Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic,
54 USA

55 ²⁰Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA

56 ²¹Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

57 ²²Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville,
58 TN, USA

59 ²³Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, the
60 Netherlands

61 ²⁴Department of Urology, Emory University School of Medicine, Atlanta, GA, USA

62 ²⁵Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, CA, USA

63 ²⁶Department of Urology, Royal Melbourne Hospital and University of Melbourne, Australia

64 ²⁷Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA

65 ²⁸Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

66 ²⁹Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA

67 ³⁰Mayo Clinic Department of Urology, Rochester, MN, USA

68 ³¹Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA

69 ³²Department of Urology, University of Pittsburgh School of Medicine, PA, USA

70 ³³Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

71 ³⁴University of Chicago Comprehensive Cancer Center, Chicago, IL, USA

72 ³⁵Urological Research Network, Miami Lakes, FL, USA

73 ³⁶Departments of Urology and Population Health, New York University Langone Health and Manhattan
74 Veterans Affairs Medical Center, New York, NY, USA

75 ³⁷Department of Urology, Oregon Health and Science University, Portland, OR, USA

76 ³⁸Genesis Healthcare Partners, Department of Urology, University of California, San Diego, CA, USA

77 ³⁹Division of Urology, NorthShore University Health System, Evanston, IL, USA

78 ⁴⁰Departments of Epidemiology and Population Health, Biomedical Data Science, and Genetics, Stanford
79 University, Stanford, CA, USA

80 ⁴¹These authors contributed equally to the first authorship.

81 ⁴²These authors contributed equally to the senior authorship.

82

83 Correspondence to John S. Witte (jswitte@stanford.edu)

84

85 **Descriptive running head:** Genetics of prostate cancer conversion from active surveillance

86 **Keywords (MeSH Headings):** prostatic neoplasms; prostate; genome-wide association study,

87 genetics

88 **Support:** NIH grant P50CA180995; CIDR Contract # HHSN268201700006I

89 **Abstract**

90 Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance
91 (AS) as their initial management strategy. While this may reduce the side effects of treatment for
92 prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most
93 heritable cancers, and genetic factors that predispose to aggressive tumors may help
94 distinguish men who are more likely to discontinue AS. To investigate this, we undertook a
95 multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially
96 elected AS and were followed over time for the potential outcome of conversion from AS to
97 active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs)
98 associated with conversion, 15 of which were not previously associated with PC risk. We found
99 two genes associated with conversion (*MAST3*, $p = 6.9 \times 10^{-7}$ and *GAB2*, $p = 2.0 \times 10^{-6}$).
100 Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC
101 was positively associated with conversion (e.g., comparing the highest to the two middle deciles
102 gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing
103 values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated
104 with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95%
105 CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize
106 the decision of AS—or the intensity of monitoring on AS—*versus* treatment for the initial
107 management of patients with low-risk PC.

108 **Introduction**

109 Active surveillance (AS) is now more widely implemented as an initial management strategy for
110 many men with lower-risk prostate cancer (PC [MIM: 176807])¹. PC that is unlikely to invade
111 surrounding tissue or metastasize according to characteristics at diagnosis is considered “low-
112 risk” or “favorable-intermediate risk”². Recent work in the United States Veterans Administration
113 (VA) Health Care System^{3,4} and in Sweden⁵ indicates that a majority of men with low-risk PC
114 are being managed with AS. Determining which patients most benefit from early active
115 treatment *versus* AS, however, and how intensive the surveillance protocol should be, remains
116 a challenge.

117

118 A major drawback of AS for low-risk PC is the possibility of misclassifying patients with life-
119 threatening disease. In fact, over a 10-year follow-up period, 20-40% of men initially managed
120 with AS later have more aggressive cancer⁶. While the impact of delayed treatment is unknown,
121 up to 50% of men in one AS series of studies experienced biochemical recurrence after active
122 treatment⁷. These uncertainties and challenges in accurately discriminating between indolent
123 and aggressive PC may prompt men to err on the side of early treatment resulting in
124 unnecessary side effects and worse health-related quality of life, or conversely result in delays
125 in therapy for men who are likely to benefit from it. Many men have such low-risk disease that
126 they do not need the biopsies or scans with the frequency with which they have typically been
127 performed. Recent work suggests that the likelihood of risk reclassification of an individual
128 patient’s disease might be predicted for at least four years of AS⁸. Thus, it may be possible
129 reduce the intensity of surveillance for many men with the lowest-risk tumors.

130

131 A key outstanding question is how to best distinguish among low- and high-risk tumors for AS
132 decisions. Promising recent developments for enhancing clinical risk assessment include multi-
133 parametric MRI with targeted prostate biopsy and tissue-based genomic testing^{9,10}. Another

134 potentially valuable approach is incorporating germline genetic information for PC via a
135 polygenic risk score¹¹. PC is one of the most heritable of common cancers, with germline
136 genetic factors accounting for over 40% of the variability in this disease^{12–15}. We and others
137 have identified from genome-wide association studies (GWAS) 269 common germline genetic
138 variants associated with PC susceptibility that explain a substantial proportion of disease
139 heritability^{16–43}. Combining these PC risk variants together into a genetic risk score (GRS) may
140 provide a more discriminatory biomarker not only for PC risk, but also potentially for predicting
141 conversion from AS to treatment^{44–47}. Moreover, we recently have discovered genetic variants
142 that explain variability in PSA levels⁴⁸. Since PSA is a critical component to monitoring men
143 undergoing AS, incorporating this information may also help to identify ideal AS candidates.
144

145 To evaluate the potential value of incorporating germline genetic information into the shared
146 decision-making process for AS, we present findings from a large, multi-institutional GWAS of
147 men diagnosed with PC enrolled in an AS program. We report novel variants and genes, and
148 genetic risk scores associated with conversion from AS to treatment.
149

149

150 **Material and Methods**

151 *Participants*

152 The primary study participants came from 28 institutions in the US, Canada, the Netherlands,
153 and Australia. We recently reported on the clinicopathological characteristics of conversion to
154 treatment in this population⁴⁹. The initial study population included 7,279 men diagnosed with
155 PC between 1991 and 2018 who elected AS for their initial management. We also included an
156 additional 593 AS patients from the University of Texas MD Anderson Cancer Center as
157 replication samples, described below. Patients' blood or tissue samples were collected to
158 conduct germline genetic analyses. The AS protocols varied among participating institutions,
159 reflecting real-world practice patterns^{50–53}, and we did not impose strict inclusion/exclusion

160 criteria based on the AS protocol. Patient demographic and clinical variables were collected and
161 managed using the Research Electronic Data Capture (REDCap) software^{54,55}. Men without
162 data on the duration of AS (235, 3.2%) and those managed with AS for less than six months
163 (269, 3.7%) were excluded, leaving 6,775 men for potential inclusion in the GWAS. This study
164 was approved by the institutional review board at each institution, all participants provided
165 written informed consent, and all participating institutions signed a material transfer and data
166 use agreement.

167

168 *Clinical and Demographic Factors*

169 We collected PC characteristics at diagnosis, including the age at diagnosis, Gleason grade
170 group (GG), PSA level, clinical tumor stage (cT), and the number of cancerous biopsy cores at
171 diagnosis. Grade groups correspond to the following Gleason scores (GS): GG1 ~ GS ≤ 6 ; GG2
172 ~ GS 3+4; GG3 ~ GS 4+3; GG4 ~ GS 8; GS 5 ~ GS 9 or 10⁵⁶. Study participants were classified
173 into three risk groups (low-, intermediate-, and high-risk) based on our modification of guidelines
174 from the National Comprehensive Cancer Network (NCCN) and the American Urological
175 Association (AUA). We did not strictly follow these guidelines because we were unable to
176 distinguish between cT2a, cT2b, and cT2c, and we did not have data on PSA density (serum
177 PSA concentration divided by prostate volume). Therefore, *low-risk* patients met the following
178 criteria: Gleason grade group 1 (GG1) (Gleason score 3+3), PSA <10 ng/mL, clinical-stage cT1,
179 and ≤ 3 positive biopsy cores. *Intermediate-risk* patients had any of the following without any
180 high-risk or high-volume criteria: GG2 (Gleason 3+4), PSA 10-20 ng/mL, or stage cT2. *High-risk*
181 patients had any of the following: \geq GG3 (\geq Gleason 4+3), PSA ≥ 20 ng/mL, stage \geq cT3, or ≥ 4
182 positive biopsy cores of any GG.

183

184 Conversion occurred when a patient received treatment following AS. The reason for
185 withdrawing from AS to begin treatment was reported as due to “upgrading”, “upstaging”, “PSA

186 progression”, “anxiety”, and/or “other” reasons. Note that in our survival analysis (below),
187 individuals who converted due to anxiety were censored and do not contribute events in our
188 analysis. We used the ADMIXTURE software program to infer genetic ancestry from
189 uncorrelated SNPs, according to major reference populations in the 1000 Genomes Project
190 (European, African, East/South Asian combined, and Admixed American)⁵⁷.

191

192 *Genotyping and Imputation*

193 In total, 6,324 participants were genotyped on the Illumina Infinium Multi-Ethnic Global Array
194 (MEGA), including custom content, at the NIH Center for Inherited Disease Research (CIDR) at
195 Johns Hopkins University. Genotypes were called using GenomeStudio version 2011.1,
196 Genotyping Module version 1.9.4, and GenTrain Version 1.0. The full array with custom content
197 consisted of 1,760,143 SNPs.

198

199 After genotyping, the median SNP call rate was 99.94%, and the error rate estimated from 122
200 pairs of planned study duplicates was 1.3×10^{-6} . Samples and variants were excluded if they had
201 a sample or genotyping call rate $< 98\%$. We limited our analyses to variants with a minor allele
202 frequency (MAF) $\geq 1\%$. Variants were screened for deviations from Hardy-Weinberg equilibrium
203 with a filter threshold of $p = 6.5 \times 10^{-4}$. A total of 856,077 genotyped SNPs remained after these
204 quality control (QC) steps. Unmeasured genetic variants were imputed using the Trans-Omics
205 for Precision Medicine (TOPMed) Imputation Server, with 97,256 reference samples and
206 308,107,085 SNPs. Variants with imputation quality (INFO) score < 0.3 were excluded, leaving
207 a total of 22,691,641 SNPs successfully imputed. After QC steps, a total of 5,936 samples
208 genotyped at CIDR remained for inclusion in the GWAS.

209

210 Furthermore, we included in our analysis an additional 593 AS patients from MD Anderson
211 previously genotyped on the Illumina Infinium OncoArray-500K BeadChip Array. This array was

212 primarily developed to study cancer predisposition and risk. Genotypes were called using
213 GenomeStudio version 2011.1. The full array consisted of 500,000 SNPs. Genotype QC
214 procedures and imputation for the PRACTICAL OncoArray have been described previously¹⁵.
215 Briefly, imputation was performed without pre-phasing with SHAPEIT2 based on the 1000
216 Genomes Phase 3 release reference panel. In total, 21,299,194 SNPs were successfully
217 imputed, and 10,109,977 variants with $MAF \geq 1\%$ on autosomal chromosomes 1-22 and sex
218 chromosome X.

219

220 *GWAS of Conversion from AS to Treatment*

221 The variants with $MAF \geq 1\%$ on autosomal chromosomes 1-22 and sex chromosome X were
222 tested for their association with time to conversion from AS to treatment among the 5,222 men
223 of European genetic ancestry genotyped by CIDR. Patients who converted due to anxiety were
224 censored because the event of interest was converting due to a change in the cancer clinical
225 characteristics. Per-allele hazard ratios (HRs), 95% confidence intervals (CIs), and
226 corresponding p-values were calculated from Cox proportional hazards models. HRs were
227 adjusted for age at diagnosis and the first 10 genetic principal components to address potential
228 population stratification or cryptic relatedness. Adjusted HRs were calculated using the
229 gwasurvivr package in R⁵⁸. For any variants associated with conversion, we examined the Cox
230 models' proportional hazards assumption.

231

232 Following the GWAS discovery phase, the potential associations were tested for replication in
233 an independent GWAS among 1,139 men also genotyped by CIDR (but of non-European
234 ancestry) and the 425 MD Anderson samples of European genetic ancestry (excluding other
235 ancestries). Again, variants with $MAF \geq 1\%$ on autosomal chromosomes and sex chromosome
236 X were tested for their association with conversion within major ancestral populations (i.e.,
237 European, African, Asian, and Admixed American). For the MD Anderson patients, 9,962,324

238 variants were tested in a Cox proportional hazards model adjusted for age at PC diagnosis and
239 ancestry principal components.

240

241 Results from the GWAS were combined with a fixed-effects inverse-variance-weighted meta-
242 analysis using METAL⁵⁹. All statistical tests were two-sided. Marginal P values less than 5×10^{-8}
243 were considered statistically significant. We defined a locus as the 1 megabase (Mb) region
244 surrounding the sentinel variant (500 kilobase pairs flanking each side). To identify
245 independently associated variants, within each 1 Mb region we performed clumping on the
246 association results using PLINK v1.9 using a linkage disequilibrium threshold $r^2 < 0.5$.

247

248 *Transcriptome-Wide Association Study of Conversion from AS to Treatment*

249 To identify additional genes associated with time to conversion, we conducted a transcriptome-
250 wide association analysis (TWAS), which models genetically imputed transcript levels and has a
251 lower multiple testing burden compared to single-variant analysis. We applied the MetaXcan
252 analytic pipeline to our GWAS summary statistics and associated genetically predicted
253 expression of approximately 22,000 genes across 49 tissue reference datasets from GTEx
254 (version 8)⁶⁰. Tissue-specific associations were aggregated using S-MultiXcan to obtain cross-
255 tissue p-values for each gene⁶⁰. Associations were considered statistically significant at the
256 Bonferroni-corrected alpha level of 2.2×10^{-6} (i.e., $0.05/22,535$ genes).

257

258 *Genetic Risk Scores*

259 Genetic risk scores (GRS) were constructed by summing variant-specific weighted allelic
260 dosages for the samples genotyped by CIDR. The initial GRS included the 269 PC risk variants
261 reported in the largest trans-ancestry GWAS meta-analysis of PC⁴³. Specifically, for patient i ,
262 $GRS_i = \sum_{m=1}^M w_m g_{im}$, where g_{im} is the genotype dosage for patient i , and variant m , and w_m is
263 the variant weight on the log odds ratio scale from the published literature (i.e., the meta-

264 analysis for the GRS_{PC}). M is the total number of variants included in the GRS ($M = 269$ for the
265 GRS_{PC}). A second GRS was developed for the genetic basis of serum PSA levels. This GRS_{PSA}
266 included 36 variants and their corresponding weights from a GWAS of PSA levels among
267 cancer-free men.⁴⁸ The associations between these GRS and conversion were estimated using
268 multivariable Cox proportional hazards models. Minimally adjusted Cox models included age
269 and the first 10 genetic principal components. Fully adjusted Cox models also included Gleason
270 grade group (GG1, GG2, or \geq GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or
271 cT3/cT4); and number of positive biopsy cores (1-2, 3, or \geq 4). The GRS was modeled as a
272 categorical variable according to deciles of the distribution, and HRs for each decile were
273 estimated with the 40-60th percentile group as the reference.

274

275 *Clinical Utility of the GRS*

276 The potential utility of the GRS was evaluated by comparing how the top and bottom deciles of
277 the GRS distribution modified conversion rates within the three PC clinicopathological risk
278 categories (i.e., low-, intermediate-, and high-). For the top and bottom GRS deciles (top 10th
279 percentile and bottom 10th percentile, respectively) we plotted Kaplan–Meier curves of
280 conversion within each PC clinicopathological risk category and tested the difference between
281 each pair of curves with the log-rank test.

282

283 To evaluate the overall discriminative capacity of the GRS (i.e., not just the decile tails), we
284 calculated the area under the ROC Curve (AUC) in the discovery sample using regression
285 models of time to conversion. We used Chambless and Diao’s estimator of cumulative AUC for
286 right-censored time-to-event data, which is a summary measure given by the integral of AUC on
287 $[0, \max(\text{times})]$ weighted by the estimated probability density of the time-to-event outcome⁶¹. A
288 baseline AUC was calculated for the model that included age and the first 10 principal
289 components. This model was then expanded to further include PC clinical characteristics listed

290 above for the multivariable Cox model, followed by GRS_{PC} and GRS_{PSA} (individually and
291 together).

292

293 **Results**

294 *Study Population*

295 Details of the discovery and replication samples that met inclusion criteria are presented in
296 **Table S1**. Clinically, most men had low-risk PC (3,639, 70%) and/or features of low-risk, low-
297 volume disease: GG1 (4,819, 92%), 1-2 positive biopsy cores (4,113, 79%), and a median PSA
298 at diagnosis of 5 ng/mL. Using genetic information to infer ancestry, 88% were classified as
299 European ancestry. The demographic and clinicopathological characteristics of the replication
300 samples had a similar pattern as the discovery samples, except that the proportion of high-risk
301 PC was higher for men of Asian genetic ancestry ($n = 43$; 18%) than of European ancestry ($n =$
302 599; 11%); **Table S1**). Baseline characteristics were missing for the following proportion of
303 study participants: age at diagnosis (<0.1%), GG group (<0.1%), PSA concentration (3.3%),
304 clinical tumor stage (6.9%), number of positive biopsy cores (2.5%), and risk-group classification
305 (<0.1%).

306

307 *Genome-Wide Association Study of Conversion from AS to Treatment*

308 Our approach to the GWAS discovery, replication, and meta-analysis is outlined in **Figure 1**.
309 The median follow-up time for patients in this multicenter study was 6.7 years. Of the 2,260
310 patients who converted from AS to treatment, 126 (5.6%) converted due to anxiety and were
311 censored in our time-to-event analyses. Our primary discovery GWAS yielded 14 independent
312 lead SNPs (i.e., p -value $< 5 \times 10^{-8}$ at each locus of size 1Mb) (**Figure 2a**). We replicated 1 of the
313 signals at a p -value level less than $0.05/14$ (≈ 0.0036) in the replication meta-analysis. In the
314 combined meta-analysis of discovery and replication GWAS, we detected four additional SNPs
315 independently associated with conversion to treatment (**Figure 2b**). Q-Q plots for the discovery

316 GWAS and the combined meta-analysis did not suggest inflation of test statistics due to
317 systematic bias such as population substructure (genomic inflation factor =1 and 1.02,
318 respectively; **Figure S1**).

319
320 Of the 18 SNPs, four were common (MAF > 0.01) and the remainder were low frequency (MAF
321 = 0.01) (**Table 1**). Three were located within 1 Mb of previous PC GWAS-identified variants,
322 although they were not in linkage disequilibrium with these variants ($r^2 < 0.3$). These were:
323 intronic SNP rs4721243 of *MAD1L1* (MIM: 602686) on chromosome 7 (CIDR European GWAS
324 $HR = 5.65$, $P = 7 \times 10^{-10}$); rs1404610 near *GLI2* (MIM: 165230; combined meta-analysis $HR =$
325 3.74 , $P = 5.4 \times 10^{-10}$) on chromosome 2; and rs74874116 near *GATA5* (MIM: 611496; CIDR
326 European $HR = 2.67$, $P = 1.47 \times 10^{-9}$) on chromosome 20.

327
328 *Transcriptome-Wide Association Study of Conversion from AS to Treatment*

329 In the multi-tissue TWAS analysis using S-MultiXcan, the imputed expression levels of two
330 genes were associated with conversion after Bonferroni correction for multiple testing: *MAST3*
331 (MIM: 612258; P-value= 6.9×10^{-7}) and *GAB2* (MIM: 606203; P-value= 2.0×10^{-6}). Imputed
332 expression levels of two other genes suggested association with conversion: *ARRDC2* (P-
333 value= 2.7×10^{-5}) and *CELSR1* (MIM: 604523; P-value= 9.5×10^{-5}). When looking only at
334 prostate tissue, we observed modest associations for *MAST3* (P-value=0.08) and *GAB2* (P-
335 value= 4.1×10^{-4}), as well as a suggestive association between imputed expression of the gene
336 *ZNF644* (MIM: 614159) and conversion (P-value= 9.9×10^{-5}).

337
338 *Genetic Risk Scores and Conversion from AS to Treatment*

339 Increasing GRS for PC susceptibility (GRS_{PC}) was positively associated with conversion from
340 AS to treatment, even after adjusting for clinical covariates (**Figure 3a**; **Table S2**). The fully

341 adjusted HR for conversion for men in the top decile of the GRS_{PC} compared to the middle two
342 deciles was 1.13 (95% CI, 0.94-1.36; **Figure 3a; Table S2**). Men in the bottom 10th percentile of
343 the GRS_{PC} distribution had a significantly lower conversion rate than the middle two deciles of
344 the GRS_{PC} (HR=0.69; 95% CI, 0.56-0.86; **Figure 3a; Table S2**).

345

346 From the 36-variant GRS for PSA concentration (GRS_{PSA}), we observed the opposite pattern:
347 increasing GRS_{PSA} was inversely associated with conversion (**Figure 3b; Table S3**). Compared
348 to the 40-60th percentiles, men in the bottom 10th percentile of the PSA GRS distribution
349 experienced a shorter time to conversion (fully adjusted HR=1.25; 95% CI, 1.04-1.50; **Figure**
350 **3b; Table S3**).

351

352 *Potential Clinical Utility of the GRS*

353 The time to conversion in the low- and intermediate-risk groups varied depending on whether
354 men were in the top or bottom deciles of the GRS_{PC} and GRS_{PSA} distributions (**Figure 4**). For
355 GRS_{PC} , the Kaplan-Meier curves contrasting the top *versus* bottom deciles were significantly
356 different for the low- and intermediate-risk groups ($p=3 \times 10^{-5}$ and $p=0.016$, respectively).
357 Similarly, the top and bottom deciles of the GRS_{PSA} differed for the intermediate-risk groups
358 ($p=0.003$). There was no clear difference between the deciles of GRS_{PC} or GRS_{PSA} in patients
359 with high-risk disease.

360

361 A baseline model including age at diagnosis and principal components achieved an AUC = 0.55
362 for time to conversion. This was substantially improved by incorporating the clinical
363 characteristics into the model: AUC = 0.653 (**Table S4**). Adding the GRS_{PC} to this model
364 resulted in modest improvement (AUC=0.659). Augmenting this model with GRS_{PSA} produced
365 minimal improvement (AUC = 0.661).

366

367 **Discussion**

368 In this GWAS of PC patients managed with AS, we detected 18 novel SNPs and two candidate
369 genes associated with conversion. We further found that GRS for PC susceptibility in addition to
370 PSA level were associated with conversion, providing information beyond conventional clinical
371 and pathologic measures of the disease. These findings provide preliminary support for using
372 germline genetic information to inform the initial management of men with newly diagnosed,
373 clinically localized PC.

374

375 Of the 18 SNPs associated with conversion, 15 were not previously associated with PC risk.
376 These include a low-frequency (MAF = 0.01) intronic variant, rs4721243 at *MAD1L1*, at a
377 previously identified PC locus⁴³. The SNP was uncorrelated with the previously reported
378 genome-wide significant PC SNP at the locus (rs4513875, $r^2 = 0.012$ in the 1000 Genomes
379 global reference data). One detected SNP (rs74874116) was 32kb away from a PC-associated
380 indel (rs139135938), with little correlation ($r^2 = 0.015$ in 1000 Genomes). The neighboring
381 gene, *GATA5*, encodes a transcription factor that contains two GATA-type zinc fingers and is
382 required during cardiovascular development⁶². This gene contains two variants previously
383 associated with benign prostatic hyperplasia (MIM: 600082) and associated lower urinary tract
384 symptoms⁶³ (MIM: 618612). Another SNP in a PC risk locus was rs1404610, nearby *GLI2*, a
385 transcription factor that one study found regulates the growth and tumorigenicity of prostate
386 cells⁶⁴.

387

388 Many of the novel SNPs we found to be associated with conversion are intronic, including SNPs
389 in genes involved in cellular signaling, growth, and differentiation. *PRDM16* (MIM: 605557),
390 where rs6658664 is located, is associated with evasion of apoptosis by prostatic cancer cells⁶⁵.
391 Intronic SNP rs115861550 in *VAV2* (MIM: 600428) is upregulated in human PC tumors and is a
392 prognostic indicator for poor outcome⁶⁶. Another intronic SNP, *EBF3* (MIM: 607407), has been

393 shown to regulate the expression of genes involved in cell growth, proliferation, and apoptosis⁶⁷.
394 *RECQL5* (MIM: 603781), where SNP rs820198 is located, regulates DNA repair intermediate
395 structures, and studies have observed elevated *RECQL5* expression in other cancers such as
396 breast (MIM: 114480) and bladder (MIM: 109800)^{68–70}. SNP rs820198 is annotated to an active
397 CTCF (CCCTC-binding factor) binding site, and CTCF expression is linked to poor outcome in
398 prostate cancer⁷¹. Although intergenic, SNP rs77112978 is near *NEDD4L* (MIM: 606384),
399 whose expression is decreased in PC⁷². Intergenic SNP rs55850837-A, associated with
400 conversion in our study, was associated with reduced body mass index⁷³ and body fat
401 percentage⁷⁴ in the phenome-wide association data curated by the IEU OpenGWAS Project⁷⁵.
402 SNP rs12452625, a UTR'3 variant of *RFNG* (MIM: 602578) gene, is correlated with variants
403 associated with multiple traits, including heel bone mineral density, lung function, and waist-hip
404 ratio^{76,77}. This SNP is also predicted to be a functional target of microRNA hsa-miR-629-3p,
405 which may serve as a biomarker for lung metastases of triple-negative breast cancer⁷⁸.
406
407 Our TWAS suggests a possible role for *MAST3* and *GAB2* in conversion. A study described
408 *MAST3* as an inflammatory bowel disease (IBD) susceptibility gene that regulates NF-κB
409 activity through TLR4⁷⁹. Two recent studies have described increased risk for PC in men with
410 IBD (MIM: 601458)^{80,81}. Regarding *GAB2*, the knockdown of this gene in PC cells altered the
411 expression of over 1,200 genes and inhibited p53 signaling⁸².
412
413 We found that the PC GRS based on 269 known risk variants was positively associated with
414 conversion. Moreover, a PSA GRS based on 36 known genetic variants for PSA levels exhibited
415 a weak inverse association with conversion. We expected these GRS to have opposite
416 directions of effect on conversion, given that the PSA GRS may reflect the potential
417 ascertainment of higher-risk PC in men with lower genetically predicted PSA levels. While the

418 overall GRS only contributed modest model discrimination beyond established risk factors for
419 conversion, the associations observed in the tails (i.e., deciles) of the GRS distribution were
420 most pronounced among men in low and intermediate clinicopathological categories. This
421 finding suggests that men with lower-risk disease, but high PC GRS (or low PSA GRS) may be
422 more likely candidates for early treatment or possibly a higher intensity of surveillance. A recent
423 study of European ancestry men with low-risk PC managed on AS reported associations
424 between higher PC GRS with more positive cores and with bilateral tumor location at diagnostic
425 and surveillance biopsy⁸³; note that ~50% of the men in this previous study are also included
426 here, comprising ~10% of our study population.

427

428 Strengths of this study include leveraging a large, multi-institutional collaborative study of AS to
429 model the effects of genetic risk variants independent of clinical risk parameters. Sixty-three
430 percent of the replication sample (n = 714) were men of non-European genetic ancestry,
431 allowing us to test the generalizability of the SNPs discovered in the European sample. Our
432 GRS included the most recently available GWAS weights from PC and PSA. Limitations of our
433 study included the lack of confirmatory or surveillance biopsies to reduce misclassification of
434 clinical parameters at diagnosis and follow-up. In addition, conversion could conflate disease
435 progression with patient anxiety and/or physician preference for AS management. However,
436 discontinuing AS due to anxiety was relatively uncommon in this study (about 6% of events),
437 and these cases were censored in the GWAS analysis. Furthermore, given the relatively short
438 follow-up for more robust PC outcomes, the sample sizes for PSA failure after treatment
439 (n=124), metastases (n=29), or PC-specific death (n=11) are too small for a GWAS analysis.

440

441 In summary, we have undertaken the first GWAS of conversion among men diagnosed
442 with PC. This multi-institutional study detected a genetic basis of conversion, suggesting

443 that genetic factors may provide valuable information to stratify men with PC by their
444 risk of discontinuing AS. Important future work will expand this study to more men
445 placed on AS, increasing our ability to detect genetic variants associated with
446 conversion. This may in turn help address concerns that biopsy sampling may
447 underestimate a tumor's aggressiveness and provide a more personalized approach to
448 decisions surrounding AS.

449 **Supplemental Data**

450 Supplemental data include one figure and four tables.

451

452 **Disclosures of Interests**

453 The authors declare no competing interests.

454

455 **Declarations**

456 This study was approved by the Robert H. Lurie Comprehensive Cancer Center of Northwestern
457 University Scientific Review (IRB) Committees. The approval number is STU00077147, which
458 was most recently given annual approval on 7/8/2021.

459

460 **Acknowledgements**

461 **Funding/Support:** P50CA180995 (William J. Catalona) 08/01/15 – 07/31/20 NIH/NCI SPORE
462 in Prostate Cancer PI on the SPORE grant, Center for Inherited Disease Research (CIDR)
463 award from the NCI for patient sample genotyping (X01HG009642), Urological Research
464 Foundation (William J. Catalona), NorthShore University Health System, Evanston, IL, USA
465 (Brian T. Helfand). Additional support was provided by award numbers R01CA158627 and
466 R01CA195505 (Leonard S. Marks), P50 CA186786 (Todd M. Morgan), UL1 TR000445 from
467 NCATS/NIH for Vanderbilt REDCap (Daniel A. Barocas), P50 CA097186 and K05 CA175147
468 (Janet L. Stanford), and U01 CA113913 (Martin G. Sanda) from the National Institute of Health,
469 and W81XWH-13-2-0074 (Peter R. Carroll) from the Department of Defense.

470

471 **Web Resources**

472 METAL (https://genome.sph.umich.edu/wiki/METAL_Documentation)

473 PLINK v1.9 (<https://www.cog-genomics.org/plink/>)

474 MetaXcan, S-MetaXcan (<https://github.com/hakyimlab/MetaXcan>)

475 IEU OpenGWAS Project (<https://gwas.mrcieu.ac.uk/>)

476 Online Mendelian Inheritance in Man (<http://www.omim.org>)

477

478 **Data Availability**

479 The MEGA data analyzed in this publication have been deposited in dbGap and are accessible

480 through dbGap Study Accession number phs002056.v1.p1.

481 **References**

- 482 1. Washington, S.L., Jeong, C.W., Lonergan, P.E., Herlemann, A., Gomez, S.L., Carroll, P.R.,
483 and Cooperberg, M.R. (2020). Regional Variation in Active Surveillance for Low-Risk Prostate
484 Cancer in the US. *JAMA Netw Open* 3, e2031349.
- 485 2. Mohler, J.L., Antonarakis, E.S., Armstrong, A.J., D'Amico, A.V., Davis, B.J., Dorff, T.,
486 Eastham, J.A., Enke, C.A., Farrington, T.A., Higano, C.S., et al. (2019). Prostate Cancer,
487 Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 17,
488 479–505.
- 489 3. Loeb, S., Byrne, N., Makarov, D.V., Lepor, H., and Walter, D. (2018). Use of Conservative
490 Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care
491 System From 2005-2015. *JAMA* 319, 2231–2233.
- 492 4. Parikh, R.B., Robinson, K.W., Chhatre, S., Medvedeva, E., Cashy, J.P., Veera, S., Bauml,
493 J.M., Fojo, T., Navathe, A.S., Malkowicz, S.B., et al. (2020). Comparison by Race of
494 Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans
495 From 2004 to 2018. *JAMA Netw Open* 3, e2018318.
- 496 5. Loeb, S., Folkvaljon, Y., Curnyn, C., Robinson, D., Bratt, O., and Stattin, P. (2017). Uptake of
497 Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. *JAMA Oncol* 3, 1393–1398.
- 498 6. Stolzenbach, L.F., Rosiello, G., Pecoraro, A., Palumbo, C., Luzzago, S., Deuker, M., Tian, Z.,
499 Knipper, A.-S., Pompe, R., Zorn, K.C., et al. (2020). Prostate Cancer Grade and Stage
500 Misclassification in Active Surveillance Candidates: Black Versus White Patients. *Journal of the*
501 *National Comprehensive Cancer Network* 18, 1492–1499.

502 7. Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T.,
503 Mamedov, A., and Loblaw, A. (2015). Long-term follow-up of a large active surveillance cohort
504 of patients with prostate cancer. *J Clin Oncol* 33, 272–277.

505 8. Cooperberg, M.R., Brooks, J.D., Faino, A.V., Newcomb, L.F., Kearns, J.T., Carroll, P.R.,
506 Dash, A., Etzioni, R., Fabrizio, M.D., Gleave, M.E., et al. (2018). Refined Analysis of Prostate-
507 specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. *Eur Urol* 74,
508 211–217.

509 9. Williams, C., Khondakar, N.R., Daneshvar, M.A., O'Connor, L.P., Gomella, P.T., Mehralivand,
510 S., Yerram, N.K., Egan, J., Gurram, S., Rompré-Brodeur, A., et al. (2021). The Risk of Prostate
511 Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by
512 Combined MRI-Fusion and Systematic Biopsy. *J Urol* 101097JU0000000000001941.

513 10. Eggener, S.E., Rumble, R.B., Armstrong, A.J., Morgan, T.M., Crispino, T., Cornford, P., van
514 der Kwast, T., Grignon, D.J., Rai, A.J., Agarwal, N., et al. (2020). Molecular Biomarkers in
515 Localized Prostate Cancer: ASCO Guideline. *J Clin Oncol* 38, 1474–1494.

516 11. Black, M.H., Li, S., LaDuca, H., Lo, M., Chen, J., Hoiness, R., Gutierrez, S., Tippin-Davis,
517 B., Lu, H., Gielzak, M., et al. (2020). Validation of a prostate cancer polygenic risk score.
518 *Prostate* 80, 1314–1321.

519 12. Langeberg, W.J., Isaacs, W.B., and Stanford, J.L. (2007). Genetic etiology of hereditary
520 prostate cancer. *Front Biosci* 12, 4101–4110.

521 13. Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M.,
522 Pukkala, E., Skytthe, A., and Hemminki, K. (2000). Environmental and heritable factors in the
523 causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J*
524 *Med* 343, 78–85.

- 525 14. Narod, S. (1999). Genetic epidemiology of prostate cancer. *Biochim Biophys Acta* 1423, F1-
526 13.
- 527 15. Schumacher, F.R., Al Olama, A.A., Berndt, S.I., Benlloch, S., Ahmed, M., Saunders, E.J.,
528 Dadaev, T., Leongamornlert, D., Anokian, E., Cieza-Borrella, C., et al. (2018). Association
529 analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat*
530 *Genet* 50, 928–936.
- 531 16. Ahn, J., Kibel, A.S., Park, J.Y., Rebbeck, T.R., Rennert, H., Stanford, J.L., Ostrander, E.A.,
532 Chanock, S., Wang, M.-H., Mittal, R.D., et al. (2011). Prostate cancer predisposition loci and
533 risk of metastatic disease and prostate cancer recurrence. *Clin Cancer Res* 17, 1075–1081.
- 534 17. Amin Al Olama, A., Kote-Jarai, Z., Schumacher, F.R., Wiklund, F., Berndt, S.I., Benlloch, S.,
535 Giles, G.G., Severi, G., Neal, D.E., Hamdy, F.C., et al. (2013). A meta-analysis of genome-wide
536 association studies to identify prostate cancer susceptibility loci associated with aggressive and
537 non-aggressive disease. *Hum Mol Genet* 22, 408–415.
- 538 18. Bao, B.-Y., Pao, J.-B., Huang, C.-N., Pu, Y.-S., Chang, T.-Y., Lan, Y.-H., Lu, T.-L., Lee, H.-
539 Z., Chen, L.-M., Ting, W.-C., et al. (2012). Significant associations of prostate cancer
540 susceptibility variants with survival in patients treated with androgen-deprivation therapy. *Int J*
541 *Cancer* 130, 876–884.
- 542 19. Bensen, J.T., Xu, Z., Smith, G.J., Mohler, J.L., Fontham, E.T.H., and Taylor, J.A. (2013).
543 Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS
544 and candidate SNPs in African-Americans and European-Americans. *Prostate* 73, 11–22.
- 545 20. Chen, M., Huang, Y.-C., Yang, S., Hsu, J.-M., Chang, Y.-H., Huang, W.J.-S., and Chen, Y.-
546 M.A. (2010). Common variants at 8q24 are associated with prostate cancer risk in Taiwanese
547 men. *Prostate* 70, 502–507.

548 21. Eeles, R.A., Kote-Jarai, Z., Giles, G.G., Olama, A.A.A., Guy, M., Jugurnauth, S.K.,
549 Mulholland, S., Leongamornlert, D.A., Edwards, S.M., Morrison, J., et al. (2008). Multiple newly
550 identified loci associated with prostate cancer susceptibility. *Nat Genet* 40, 316–321.

551 22. Eeles, R.A., Olama, A.A.A., Benlloch, S., Saunders, E.J., Leongamornlert, D.A.,
552 Tymrakiewicz, M., Ghoussaini, M., Luccarini, C., Dennis, J., Jugurnauth-Little, S., et al. (2013).
553 Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping
554 array. *Nat Genet* 45, 385–391, 391e1-2.

555 23. FitzGerald, L.M., Kwon, E.M., Conomos, M.P., Kolb, S., Holt, S.K., Levine, D., Feng, Z.,
556 Ostrander, E.A., and Stanford, J.L. (2011). Genome-wide association study identifies a genetic
557 variant associated with risk for more aggressive prostate cancer. *Cancer Epidemiol Biomarkers*
558 *Prev* 20, 1196–1203.

559 24. Gudmundsson, J., Sulem, P., Rafnar, T., Bergthorsson, J.T., Manolescu, A., Gudbjartsson,
560 D., Agnarsson, B.A., Sigurdsson, A., Benediktsdottir, K.R., Blondal, T., et al. (2008). Common
561 sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. *Nat Genet* 40,
562 281–283.

563 25. Gudmundsson, J., Besenbacher, S., Sulem, P., Gudbjartsson, D.F., Olafsson, I.,
564 Arinbjarnarson, S., Agnarsson, B.A., Benediktsdottir, K.R., Isaksson, H.J., Kostic, J.P., et al.
565 (2010). Genetic correction of PSA values using sequence variants associated with PSA levels.
566 *Sci Transl Med* 2, 62ra92.

567 26. Helfand, B.T., Loeb, S., Cashy, J., Meeks, J.J., Thaxton, C.S., Han, M., and Catalona, W.J.
568 (2008). Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer
569 susceptibility alleles. *J Urol* 179, 2197–2201; discussion 2202.

570 27. Helfand, B.T., Kan, D., Modi, P., and Catalona, W.J. (2011). Prostate cancer risk alleles
571 significantly improve disease detection and are associated with aggressive features in patients
572 with a “normal” prostate specific antigen and digital rectal examination. *Prostate* 71, 394–402.

573 28. Lange, E.M., Johnson, A.M., Wang, Y., Zuhlke, K.A., Lu, Y., Ribado, J.V., Keele, G.R., Li, J.,
574 Duan, Q., Li, G., et al. (2014). Genome-wide association scan for variants associated with early-
575 onset prostate cancer. *PLoS One* 9, e93436.

576 29. Lange, E.M., Salinas, C.A., Zuhlke, K.A., Ray, A.M., Wang, Y., Lu, Y., Ho, L.A., Luo, J., and
577 Cooney, K.A. (2012). Early onset prostate cancer has a significant genetic component. *Prostate*
578 72, 147–156.

579 30. Lin, D.W., FitzGerald, L.M., Fu, R., Kwon, E.M., Zheng, S.L., Kolb, S., Wiklund, F., Stattin,
580 P., Isaacs, W.B., Xu, J., et al. (2011). Genetic variants in the LEPR, CRY1, RNASEL, IL4, and
581 ARVCF genes are prognostic markers of prostate cancer-specific mortality. *Cancer Epidemiol*
582 *Biomarkers Prev* 20, 1928–1936.

583 31. Loeb, S., Carter, H.B., Walsh, P.C., Isaacs, W.B., Kettermann, A., Tanaka, T., Ferrucci, L.,
584 and Metter, E.J. (2009). Single nucleotide polymorphisms and the likelihood of prostate cancer
585 at a given prostate specific antigen level. *J Urol* 182, 101–104; discussion 105.

586 32. Pal, P., Xi, H., Guha, S., Sun, G., Helfand, B.T., Meeks, J.J., Suarez, B.K., Catalona, W.J.,
587 and Deka, R. (2009). Common variants in 8q24 are associated with risk for prostate cancer and
588 tumor aggressiveness in men of European ancestry. *Prostate* 69, 1548–1556.

589 33. Pomerantz, M.M., Werner, L., Xie, W., Regan, M.M., Lee, G.-S.M., Sun, T., Evan, C.,
590 Petrozziello, G., Nakabayashi, M., Oh, W.K., et al. (2011). Association of prostate cancer risk
591 Loci with disease aggressiveness and prostate cancer-specific mortality. *Cancer Prev Res*
592 (Phila) 4, 719–728.

- 593 34. Sun, J., Lange, E.M., Isaacs, S.D., Liu, W., Wiley, K.E., Lange, L., Gronberg, H., Duggan,
594 D., Carpten, J.D., Walsh, P.C., et al. (2008). Chromosome 8q24 risk variants in hereditary and
595 non-hereditary prostate cancer patients. *Prostate* 68, 489–497.
- 596 35. Xu, J., Zheng, S.L., Isaacs, S.D., Wiley, K.E., Wiklund, F., Sun, J., Kader, A.K., Li, G.,
597 Purcell, L.D., Kim, S.-T., et al. (2010). Inherited genetic variant predisposes to aggressive but
598 not indolent prostate cancer. *Proc Natl Acad Sci U S A* 107, 2136–2140.
- 599 36. Goh, C.L., and Eeles, R.A. (2014). Germline genetic variants associated with prostate
600 cancer and potential relevance to clinical practice. *Recent Results Cancer Res* 202, 9–26.
- 601 37. Ishak, M.B., and Giri, V.N. (2011). A systematic review of replication studies of prostate
602 cancer susceptibility genetic variants in high-risk men originally identified from genome-wide
603 association studies. *Cancer Epidemiol Biomarkers Prev* 20, 1599–1610.
- 604 38. Kim, S.-T., Cheng, Y., Hsu, F.-C., Jin, T., Kader, A.K., Zheng, S.L., Isaacs, W.B., Xu, J., and
605 Sun, J. (2010). Prostate cancer risk-associated variants reported from genome-wide association
606 studies: meta-analysis and their contribution to genetic Variation. *Prostate* 70, 1729–1738.
- 607 39. Lindström, S., Zheng, S.L., Wiklund, F., Jonsson, B.-A., Adami, H.-O., Bälter, K.A., Brookes,
608 A.J., Sun, J., Chang, B.-L., Liu, W., et al. (2006). Systematic replication study of reported
609 genetic associations in prostate cancer: Strong support for genetic variation in the androgen
610 pathway. *Prostate* 66, 1729–1743.
- 611 40. Pomerantz, M.M., and Freedman, M.L. (2010). Genetics of prostate cancer risk. *Mt Sinai J*
612 *Med* 77, 643–654.

613 41. Na, R., Liu, F., Zhang, P., Ye, D., Xu, C., Shao, Q., Qi, J., Wang, X., Chen, Z., Wang, M., et
614 al. (2013). Evaluation of reported prostate cancer risk-associated SNPs from genome-wide
615 association studies of various racial populations in Chinese men. *Prostate* 73, 1623–1635.

616 42. Bensen, J.T., Xu, Z., McKeigue, P.M., Smith, G.J., Fontham, E.T.H., Mohler, J.L., and
617 Taylor, J.A. (2014). Admixture mapping of prostate cancer in African Americans participating in
618 the North Carolina-Louisiana Prostate Cancer Project (PCaP). *Prostate* 74, 1–9.

619 43. Conti, D.V., Darst, B.F., Moss, L.C., Saunders, E.J., Sheng, X., Chou, A., Schumacher,
620 F.R., Olama, A.A.A., Benlloch, S., Dadaev, T., et al. (2021). Trans-ancestry genome-wide
621 association meta-analysis of prostate cancer identifies new susceptibility loci and informs
622 genetic risk prediction. *Nat Genet* 53, 65–75.

623 44. Chen, H., Liu, X., Brendler, C.B., Ankerst, D.P., Leach, R.J., Goodman, P.J., Lucia, M.S.,
624 Tangen, C.M., Wang, L., Hsu, F.-C., et al. (2016). Adding genetic risk score to family history
625 identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer
626 prevention trial. *Prostate* 76, 1120–1129.

627 45. Helfand, B.T., Kearns, J., Conran, C., and Xu, J. (2016). Clinical validity and utility of genetic
628 risk scores in prostate cancer. *Asian J Androl* 18, 509–514.

629 46. Huynh-Le, M.-P., Karunamuni, R., Fan, C.C., Thompson, W.K., Muir, K., Lophatananon, A.,
630 Tye, K., Wolk, A., Håkansson, N., Mills, I.G., et al. (2021). Common genetic and clinical risk
631 factors: association with fatal prostate cancer in the Cohort of Swedish Men. *Prostate Cancer*
632 *Prostatic Dis.*

633 47. Helfand, B.T., and Xu, J. (2021). Germline Testing for Prostate Cancer Prognosis:
634 Implications for Active Surveillance. *Urol Clin North Am* 48, 401–409.

- 635 48. Hoffmann, T.J., Passarelli, M.N., Graff, R.E., Emami, N.C., Sakoda, L.C., Jorgenson, E.,
636 Habel, L.A., Shan, J., Ranatunga, D.K., Quesenberry, C.P., et al. (2017). Genome-wide
637 association study of prostate-specific antigen levels identifies novel loci independent of prostate
638 cancer. *Nat Commun* 8, 14248.
- 639 49. Cooley, L.F., Emeka, A.A., Meyers, T.J., Helfand, B.T., Scholtens, D.M., Witte, J.S., and
640 Catalona, W.J. Factors Associated with Time to Conversion from Active Surveillance to
641 Treatment for Prostate Cancer in a Multi-institutional Cohort. *Journal of Urology Manuscript*
642 *accepted for publication*,.
- 643 50. Van Hemelrijck, M., Ji, X., Helleman, J., Roobol, M.J., van der Linden, W., Nieboer, D.,
644 Bangma, C.H., Frydenberg, M., Rannikko, A., Lee, L.S., et al. (2019). Reasons for Discontinuing
645 Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3
646 Consortium. *Eur Urol* 75, 523–531.
- 647 51. Gregg, J.R., Davis, J.W., Reichard, C., Wang, X., Achim, M., Chapin, B.F., Pisters, L.,
648 Pettaway, C., Ward, J.F., Choi, S., et al. (2020). Determining Clinically Based Factors
649 Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active
650 Surveillance Cohort. *Urology* 138, 91–97.
- 651 52. Welty, C.J., Cowan, J.E., Nguyen, H., Shinohara, K., Perez, N., Greene, K.L., Chan, J.M.,
652 Meng, M.V., Simko, J.P., Cooperberg, M.R., et al. (2015). Extended followup and risk factors for
653 disease reclassification in a large active surveillance cohort for localized prostate cancer. *J Urol*
654 193, 807–811.
- 655 53. Hamdy, F.C., Donovan, J.L., Lane, J.A., Mason, M., Metcalfe, C., Holding, P., Davis, M.,
656 Peters, T.J., Turner, E.L., Martin, R.M., et al. (2016). 10-Year Outcomes after Monitoring,

657 Surgery, or Radiotherapy for Localized Prostate Cancer. *New England Journal of Medicine* 375,
658 1415–1424.

659 54. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009).
660 Research electronic data capture (REDCap)--a metadata-driven methodology and workflow
661 process for providing translational research informatics support. *J Biomed Inform* 42, 377–381.

662 55. Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L.,
663 Delacqua, G., Delacqua, F., Kirby, J., et al. (2019). The REDCap consortium: Building an
664 international community of software platform partners. *J Biomed Inform* 95, 103208.

665 56. Gordetsky, J., and Epstein, J. (2016). Grading of prostatic adenocarcinoma: current state
666 and prognostic implications. *Diagn Pathol* 11, 25.

667 57. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of
668 ancestry in unrelated individuals. *Genome Res* 19, 1655–1664.

669 58. Rizvi, A.A., Karaesmen, E., Morgan, M., Preus, L., Wang, J., Sovic, M., Hahn, T., and
670 Sucheston-Campbell, L.E. (2019). gwasurvivr: an R package for genome-wide survival analysis.
671 *Bioinformatics* 35, 1968–1970.

672 59. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of
673 genomewide association scans. *Bioinformatics* 26, 2190–2191.

674 60. Barbeira, A.N., Pividori, M., Zheng, J., Wheeler, H.E., Nicolae, D.L., and Im, H.K. (2019).
675 Integrating predicted transcriptome from multiple tissues improves association detection. *PLOS*
676 *Genetics* 15, e1007889.

677 61. Chambless, L.E., and Diao, G. (2006). Estimation of time-dependent area under the ROC
678 curve for long-term risk prediction. *Stat Med* 25, 3474–3486.

679 62. Reiter, J.F., Alexander, J., Rodaway, A., Yelon, D., Patient, R., Holder, N., and Stainier,
680 D.Y.R. (1999). *Gata5* is required for the development of the heart and endoderm in zebrafish.
681 *Genes Dev* 13, 2983–2995.

682 63. Gudmundsson, J., Sigurdsson, J.K., Stefansdottir, L., Agnarsson, B.A., Isaksson, H.J.,
683 Stefansson, O.A., Gudjonsson, S.A., Gudbjartsson, D.F., Masson, G., Frigge, M.L., et al.
684 (2018). Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation
685 with serum levels of PSA. *Nat Commun* 9, 4568.

686 64. Thiyagarajan, S., Bhatia, N., Reagan-Shaw, S., Cozma, D., Thomas-Tikhonenko, A.,
687 Ahmad, N., and Spiegelman, V.S. (2007). Role of *GLI2* transcription factor in growth and
688 tumorigenicity of prostate cells. *Cancer Res* 67, 10642–10646.

689 65. Zhu, S., Xu, Y., Song, M., Chen, G., Wang, H., Zhao, Y., Wang, Z., and Li, F. (2016).
690 *PRDM16* is associated with evasion of apoptosis by prostatic cancer cells according to RNA
691 interference screening. *Mol Med Rep* 14, 3357–3361.

692 66. Magani, F., Peacock, S.O., Rice, M.A., Martinez, M.J., Greene, A.M., Magani, P.S., Lyles,
693 R., Weitz, J.R., and Burnstein, K.L. (2017). Targeting AR Variant-Coactivator Interactions to
694 Exploit Prostate Cancer Vulnerabilities. *Mol Cancer Res* 15, 1469–1480.

695 67. Zhao, L.Y., Niu, Y., Santiago, A., Liu, J., Albert, S.H., Robertson, K.D., and Liao, D. (2006).
696 An *EBF3*-mediated transcriptional program that induces cell cycle arrest and apoptosis. *Cancer*
697 *Res* 66, 9445–9452.

698 68. Arora, A., Abdel-Fatah, T.M.A., Agarwal, D., Doherty, R., Croteau, D.L., Moseley, P.M.,
699 Hameed, K., Green, A., Aleskandarany, M.A., Rakha, E.A., et al. (2016). Clinicopathological and
700 prognostic significance of *RECQL5* helicase expression in breast cancers. *Carcinogenesis* 37,
701 63–71.

702 69. Chen, E., Ahn, J.S., Sykes, D.B., Breyfogle, L.J., Godfrey, A.L., Nangalia, J., Ko, A.,
703 DeAngelo, D.J., Green, A.R., and Mullally, A. (2015). RECQL5 Suppresses Oncogenic JAK2-
704 Induced Replication Stress and Genomic Instability. *Cell Rep* 13, 2345–2352.

705 70. Patterson, K., Arya, L., Bottomley, S., Morgan, S., Cox, A., Catto, J., and Bryant, H.E.
706 (2016). Altered RECQL5 expression in urothelial bladder carcinoma increases cellular
707 proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. *Oncotarget*
708 7, 76140–76150.

709 71. Höflmayer, D., Steinhoff, A., Hube-Magg, C., Kluth, M., Simon, R., Burandt, E., Tsourlakis,
710 M.C., Minner, S., Sauter, G., Büscheck, F., et al. (2020). Expression of CCCTC-binding factor
711 (CTCF) is linked to poor prognosis in prostate cancer. *Molecular Oncology* 14, 129–138.

712 72. Hu, X.Y., Xu, Y.M., Fu, Q., Yu, J.J., and Huang, J. (2009). Nedd4L expression is
713 downregulated in prostate cancer compared to benign prostatic hyperplasia. *Eur J Surg Oncol*
714 35, 527–531.

715 73. UK Biobank.

716 74. Elsworth, B.L. (2017). MRC IEU UK Biobank GWAS pipeline version 1.

717 75. Elsworth, B., Lyon, M., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer, T.,
718 Haberland, V., Smith, G.D., et al. (2020). The MRC IEU OpenGWAS data infrastructure
719 (Genetics).

720 76. Kichaev, G., Bhatia, G., Loh, P.-R., Gazal, S., Burch, K., Freund, M.K., Schoech, A.,
721 Pasaniuc, B., and Price, A.L. (2019). Leveraging Polygenic Functional Enrichment to Improve
722 GWAS Power. *Am J Hum Genet* 104, 65–75.

723 77. Lotta, L.A., Wittemans, L.B.L., Zuber, V., Stewart, I.D., Sharp, S.J., Luan, J., Day, F.R., Li,
724 C., Bowker, N., Cai, L., et al. (2018). Association of Genetic Variants Related to Gluteofemoral
725 vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular
726 Risk Factors. *JAMA* 320, 2553–2563.

727 78. Wang, J., Song, C., Tang, H., Zhang, C., Tang, J., Li, X., Chen, B., and Xie, X. (2017). miR-
728 629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of
729 triple-negative breast cancer. *Breast Cancer Res* 19, 72.

730 79. Labbé, C., Goyette, P., Lefebvre, C., Stevens, C., Green, T., Tello-Ruiz, M.K., Cao, Z.,
731 Landry, A.L., Stempak, J., Annese, V., et al. (2008). MAST3: a novel IBD risk factor that
732 modulates TLR4 signaling. *Genes Immun* 9, 602–612.

733 80. Burns, J.A., Weiner, A.B., Catalona, W.J., Li, E.V., Schaeffer, E.M., Hanauer, S.B., Strong,
734 S., Burns, J., Hussain, M.H.A., and Kundu, S.D. (2019). Inflammatory Bowel Disease and the
735 Risk of Prostate Cancer. *Eur Urol* 75, 846–852.

736 81. Meyers, T.J., Weiner, A.B., Graff, R.E., Desai, A.S., Cooley, L.F., Catalona, W.J., Hanauer,
737 S.B., Wu, J.D., Schaeffer, E.M., Abdulkadir, S.A., et al. (2020). Association between
738 inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based
739 study. *Int J Cancer* 147, 2735–2742.

740 82. Qiao, X.-R., Zhang, X., Mu, L., Tian, J., and Du, Y. (2020). GRB2-associated binding protein
741 2 regulates multiple pathways associated with the development of prostate cancer. *Oncol Lett*
742 20, 99.

743 83. Xu, J., Isaacs, W.B., Mamawala, M., Shi, Z., Landis, P., Petkewicz, J., Wei, J., Wang, C.-H.,
744 Resurreccion, W.K., Na, R., et al. (2021). Association of prostate cancer polygenic risk score
745 with number and laterality of tumor cores in active surveillance patients. *Prostate* 81, 703–709.

746

747 **Figure Titles and Legends**

748 **Figure 1. Flow chart highlighting the approach and samples used in the genome-wide**

749 **association analysis.** First, we undertook a discovery GWAS in men of European ancestry.

750 Fourteen SNPs were associated with conversion ($P < 5 \times 10^{-8}$). All SNPs were evaluated for

751 replication in the replication cohorts alone and then in a meta-analysis combining the discovery

752 and replication cohorts. Four additional SNPs reached statistical significance in the combined

753 meta-analysis ($P < 5 \times 10^{-8}$).

754

755 **Figure 2. Results from the GWASs of conversion from AS to treatment (a) in 5,222**

756 prostate cancer patients of European ancestry; (b) in discovery and replication cohorts. P values

757 are for variant associations with conversion, adjusted for age and ten ancestry principal

758 components using Cox proportional hazards models. Blue dashed line denotes the genome-

759 wide significance threshold. Orange peaks indicate genome-wide significant hits ($P < 5 \times 10^{-8}$).

760 The top variants in each chromosome are annotated with their rsID.

761

762 **Figure 3. Association between time to conversion from AS to treatment (a) with the**

763 prostate cancer GRS; (b) with the prostate-specific antigen GRS . The fifth and sixth deciles of

764 prostate cancer GRS are used as the reference. Bars indicate 95% confidence intervals (CI)

765 around the hazard ratio (HR) estimates. The minimally adjusted model includes age and the first

766 10 genetic principal components. The fully adjusted model also includes Gleason grade group

767 (GG1, GG2, or \geq GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and

768 number of positive biopsy cores (1-2, 3, or \geq 4).

769

770 **Figure 4. Kaplan-Meier plots of active surveillance conversion-free probability for low,**

771 **intermediate, and high clinicopathological risk categories.** The plots are stratified by the top

772 and bottom deciles of genetic risk scores for prostate cancer (GRS_{PC} , panel a) and for PSA
773 levels (GRS_{PSA} , panel b). The curves within each risk category are compared between the top
774 and bottom GRS deciles using a log-rank test (P-values given next to corresponding curves).

Tables

Table 1. Results for 4 common and 14 variants associated with conversion from AS to treatment in a genome-wide association analysis.

rsid	Chr	Genes	Risk Allele / ref allele	RAF	HR (95% CI), p-value								
					Discovery European			Replication meta-analysis			Combined meta-analysis		
Common variants													
rs77112978	18	<i>ATP8B1</i> <i>NEDD4L</i> ^a	G/C	0.048	1.4 1	(1.23 - 1.63)	1.51 $\times 10^{-6}$	2.24	(1.38 - 3.65)	1.14 $\times 10^{-3}$	1. 47	(1.28 - 1.68)	3.26 $\times 10^{-8}$
rs55850837	18	<i>MC4R</i> <i>CDH20</i> ^a	A/G	0.050	1.4 2	(1.24 - 1.63)	3.43 $\times 10^{-7}$	1.92	(1.09 - 3.36)	0.0232	1. 45	(1.27 - 1.65)	4.03 $\times 10^{-8}$
rs17878533	19	<i>IL12RB1</i> ^b	A/G	0.651	1.2 3	(1.14 - 1.32)	4.56 $\times 10^{-8}$	0.94	(0.75 - 1.18)	0.582	1. 2	(1.12 - 1.28)	4.86 $\times 10^{-7}$
rs74874116	20	<i>RBBP8</i> <i>NL</i> <i>GATA5</i> ^a	T/G	0.028	2.6 7	(1.94 - 3.66)	1.47 $\times 10^{-9}$	1.23	(0.93 - 1.64)	0.146	1. 74	(1.41 - 2.15)	3.14 $\times 10^{-7}$
Rare variants													
rs6658664	1	<i>PRDM1</i> ^{6b}	A/G	0.014	5.1 9	(3.33 - 8.09)	3.55 $\times 10^{-13}$	0.94	(0.67 - 1.33)	0.746	1. 79	(1.37 - 2.46)	2.58 $\times 10^{-5}$
rs1404610	2	<i>LINC0101</i> <i>GLI2</i> ^a	G/A	0.012	15. 15	(4.64 - 49.5)	6.69 $\times 10^{-6}$	3.07	(1.97 - 4.79)	7.84 $\times 10^{-7}$	3. 74	(2.47 - 5.67)	5.37 $\times 10^{-10}$
rs116419656	3	<i>FAM86D</i> <i>MIR132</i> ^{4a}	G/A	0.010	6.8 9	(4.03 - 11.8)	1.95 $\times 10^{-12}$	0.96	(0.47 - 2.00)	0.923	3. 45	(2.24 - 5.32)	2.06 $\times 10^{-8}$
rs4721243	7	<i>MAD1L</i> ^{1b}	A/G	0.010	5.6 5	(3.26 - 9.8)	7 $\times 10^{-10}$	0.78	(0.5 - 1.22)	0.28	1. 70	(1.2 - 2.39)	2.6 $\times 10^{-3}$
rs113658888	8	<i>MROH</i> ^{1b}	T/C	0.011	3.8 6	(2.60 - 5.74)	2.52 $\times 10^{-11}$	1.22	(0.84 - 1.78)	0.305	2. 11	(1.6 - 2.77)	9.04 $\times 10^{-8}$
rs115861550	9	<i>VAV2</i> ^b	T/C	0.010	7.5 1	(4.48 - 12.6)	2.03 $\times 10^{-14}$	1.01	(0.69 - 1.48)	0.943	2. 05	(1.51 - 2.79)	4.26 $\times 10^{-6}$
rs3750827	10	<i>EBF3</i> ^b	A/G	0.011	2.4 2	(1.79 - 3.21)	5.05 $\times 10^{-9}$	1.78	(1.04 - 3.03)	0.035	2. 24	(1.73 - 2.89)	8.29 $\times 10^{-10}$
rs28514969	11	<i>TSPAN4</i> ^b	C/T	0.011	14. 16	(5.78 - 34.7)	6.69 $\times 10^{-9}$	1.49	(0.92 - 2.39)	0.103	2. 44	(1.6 - 3.72)	3.16 $\times 10^{-5}$
rs563064	13	<i>F10</i> ^c	A/G	0.010	34. 03	(10.4 - 111)	4.59 $\times 10^{-9}$	2.2	(1.45 - 3.34)	1.96 $\times 10^{-4}$	2. 98	(2.01 - 4.41)	4.89 $\times 10^{-8}$
rs820198	17	<i>RECQL5</i> ^b	T/C	0.010	14. 26	(6.56 - 31.0)	2.03 $\times 10^{-11}$	1.2	(0.67 - 2.17)	0.537	2. 97	(1.86 - 4.75)	5.50 $\times 10^{-6}$
rs12452625	17	<i>RFNG</i> ^d	A/G	0.011	3.8 4	(2.65 - 5.57)	1.20 $\times 10^{-12}$	1.03	(0.68 - 1.56)	0.878	2. 14	(1.62 - 2.82)	6.84 $\times 10^{-8}$
rs59027729	19	<i>HCN2</i> ^b	A/G	0.014	2.0 6	(1.58 - 2.68)	7.24 $\times 10^{-8}$	1.47	(0.92 - 2.34)	0.109	1. 90	(1.51 - 2.39)	4.25 $\times 10^{-8}$
rs116837676	19	<i>MYAD</i> ^{Mb}	A/G	0.011	5.4 2	(3.00 - 9.77)	2.01 $\times 10^{-8}$	1.72	(1.17 - 2.53)	5.66 $\times 10^{-3}$	2. 42	(1.76 - 3.34)	7.34 $\times 10^{-8}$
rs56064912	X	<i>POF1B</i> <i>MIR132</i> ^{1a}	T/G	0.010	24. 7	(8.95 - 68.3)	6.13 $\times 10^{-10}$	1.07	(0.85 - 1.36)	0.55	1. 26	(1 - 1.59)	0.0475

Chr, chromosome; Ref, reference; RAF = Risk allele frequency; HR, hazard ratio; CI, Confidence Interval. SNPs included here are those with association $P < 5 \times 10^{-8}$ either in European discovery GWAS or combined meta-analysis of all samples.

In the Genes column

^a Intergenic (genes are two flanking)

^b Intronic

^c Upstream

^d UTR3





Figure 1

Figure 2

(a)



(b)




Figure 3







Figure 4



Number at risk

Low-Risk, Top Decile	387	186	40	6
Low-Risk, Bottom Decile	424	250	57	7
Intermediate-Risk, Top Decile	108	38	11	2
Intermediate-Risk, Bottom Decile	118	55	14	1
High-Risk, Top Decile	98	27	5	1
High-Risk, Bottom Decile	52	17	3	0



Number at risk

Low-Risk, Top Decile	416	238	46	7
Low-Risk, Bottom Decile	383	210	60	11
Intermediate-Risk, Top Decile	111	49	7	0
Intermediate-Risk, Bottom Decile	122	35	8	2
High-Risk, Top Decile	66	17	3	0
High-Risk, Bottom Decile	89	19	3	0